Trial Profile

Randomized, Open-Label, Cross-Over, Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in Homozygous Familial Hypercholesterolemia Patients on Stable Lipid-Lowering Therapy

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 29 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lerodalcibep (Primary) ; Evolocumab
Indications Hyperlipoproteinaemia type IIa
Focus Registrational; Therapeutic Use
Acronyms LIBerate-003; LIBerate-HoFH
Sponsors LIB Therapeutics

Most Recent Events

27 Jan 2025 According to LIB Therapeutics media release, Professor Derick Raal, is Lead Investigator for the LIBerate HoFH trial.
27 Jan 2025 According to LIB Therapeutics media release, results from this trial were published in Lancet Diabetes & Endocrinology (Raal, F.J. et al, 2025).
27 Jan 2025 Results presented in the LIB Therapeutics Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com